Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2

Overview of attention for article published in Frontiers in immunology, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 11 news stories from 11 outlets.

RICHMOND HILL, ONTARIO--(Marketwired - Aug. 22, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"…

RICHMOND HILL, ONTARIO -- (Marketwired) -- 08/22/17 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company…

RICHMOND HILL, ONTARIO -- (Marketwired) -- 08/22/17 -- Helix BioPharma Corp. (TSX: HBP)(FRANKFURT: HBP) ("Helix" or the "Company…

RICHMOND HILL, ONTARIO -- (Marketwired) -- 08/22/17 -- Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company")…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 7 additional news stories.